FBIO

Fortress Biotech, Inc. (FBIO) 2024 Annual Report Summary

Business Context and Reporting Period

This summary covers the Annual Report on Form 10-K for Fortress Biotech, Inc. for the fiscal year ended December 31, 2024. Fortress operates as a biopharmaceutical holding company focused on acquiring and advancing assets through a network of subsidiaries and partner companies. Key entities include Journey Medical Corporation (dermatology), Checkpoint Therapeutics (oncology), Mustang Bio (oncology), and Avenue Therapeutics. The company generates revenue primarily through product sales from Journey and collaboration/milestone payments from partners.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Net revenue decreased 32% to $57.7 million. This was driven by a 95% drop in "Other Revenue" (primarily a one-time $19.0 million upfront payment from Maruho in 2023) and an 8% decline in product revenue due to higher managed care rebates and lower unit volumes for legacy products like Targadox and Exelderm.
• Expense Reduction: Total operating expenses decreased 26% to $168.1 million. R&D expenses dropped 44% to $56.6 million, largely due to workforce reductions at Mustang Bio and the transition of programs (CUTX-101 and dotinurad) to partners Sentynl and Crystalys.
• Loss Recovery: A $4.6 million gain was recorded in 2024 from the recovery of funds related to a 2021 cybersecurity incident at Journey Medical.
• Debt Restructuring: In July 2024, the company entered a new $50.0 million senior secured credit agreement with Oaktree, replacing the prior facility. The company borrowed $35.0 million initially.

Guidance, Outlook, and Material Events

• Checkpoint Acquisition: In March 2025, Checkpoint Therapeutics agreed to be acquired by Sun Pharmaceutical Industries for $4.10 per share in cash plus a contingent value right (CVR) of up to $0.70 per share upon EU approval of UNLOXCYT. Fortress expects to receive a 2.5% royalty on worldwide net sales of UNLOXCYT.
• Product Approvals:
  • UNLOXCYT (Checkpoint): Received FDA approval in December 2024 for metastatic cutaneous squamous cell carcinoma (cSCC).
  • Emrosi (Journey): Received FDA approval in November 2024 for rosacea; commercial launch occurred in March 2025.
  • CUTX-101 (Cyprium/Sentynl): NDA accepted for priority review by the FDA in January 2025 for Menkes disease, with a PDUFA date of September 30, 2025.
• Dividend Pause: In July 2024, the Board paused monthly dividend payments on the 9.375% Series A Preferred Stock to preserve cash. This action rendered the company ineligible to use Form S-3 for future equity offerings.
• Liquidity: Management believes current cash and cash equivalents are sufficient to fund operations for at least the next 12 months. However, the company expects to continue incurring operating losses and will require additional financing to fund R&D and commercialization.
• Risks: Significant risks include the uncertainty of the Checkpoint merger closing, reliance on third-party manufacturers, potential generic competition for Journey's non-patented products, and the need for substantial additional capital.

Key Facts for Investor Verification

• Checkpoint Merger Status: Verify the closing conditions and timeline for the Sun Pharma acquisition of Checkpoint, including the likelihood of achieving the EU approval milestone for the CVR.
• Preferred Stock Dividends: Monitor the status of the paused Series A Preferred Stock dividends and the company's ability to resume payments or refinance the obligation.
• Debt Covenants: Review compliance with the new Oaktree credit agreement covenants, specifically the minimum liquidity requirement ($7.0 million) and the minimum net sales test for Journey ($50.0 million trailing 12-month).
• Emrosi Commercialization: Track the commercial performance of Emrosi post-launch to assess its ability to offset declines in legacy Journey products.
• Capital Raising: Assess the company's ability to raise capital given the loss of Form S-3 eligibility, which may increase the cost and dilution of future equity offerings.